The Cure Starts Now has funded $25,255,277 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 165 grants at over 100 hospitals in 29 countries.




St. Jude's Children's Research Hospital - $15,000

Amount
$15,000.00
Date
October 2012

Establishment and Characterization of Renewable Tissue Resources for DIPG Research

DIPG Registry - $219,000

Amount
$219,000.00
Date
January 2012

Establishment of an International DIPG Registry

Texas Children's Cancer Center - $100,000

Amount
$100,000.00
Date
November 2011

Eliminating Therapy-Resistant Diffuse Intrinsic Pontine Gliomas with Oncolytic Picorna Virus SVV-001

Duke University - $82,049

Amount
$82,049.00
Date
November 2011

Preclinical Evaluation of Systemic and Direct Delivery of a PDGFR-Alpha Antibody

Doernbecher Children's Hospital - $100,000

Amount
$100,000.00
Date
November 2011

Rapid Preclinical Development of a Targeted Therapy Combination for DIPG.

Sydney Children's Hospital - $100,000

Amount
$100,000.00
Date
August 2011

Robotic screening for novel therapies for diffuse pontine gliomas

St. Jude's Children's Research Hospital - $35,000

Amount
$35,000.00
Date
September 2010

PI3K signaling effectors in DIPG

Cincinnati Children's Hospital - $35,000

Amount
$35,000.00
Date
September 2010

Establishment of a pre-clinical model for pediatric glioblastoma

Cincinnati Children's Hospital - $75,000

Amount
$75,000.00
Date
March 2010

Telomerase: A Therapeutic Target in Pediatric Brain Tumors

Weill Cornell Medical College - $91,740

Amount
$91,740.00
Date
March 2010

Phase I Study of tumor-targeting Convection-Enhanced Delivery (CED) of radio immunotherapy for Diffuse Pontine Glioma in Children.

St. Jude's Children's Research Hospital - $10,000

Amount
$10,000.00
Date
July 2009

Molecular Analysis of Diffuse Intrinsic Pontine Gliomas.

Cincinnati Children's Hospital - $50,000

Amount
$50,000.00
Date
July 2009

National expansion of the study of Radiotherapy and concurrent Bevacizumab +/- Temozolamide followed by Bevacizumab, Irinotecan +/- Temozolamide in patients with newly diagnosed high grade gliomas and DIPG.

St. Jude's Children's Research Hospital - $50,000

Amount
$50,000.00
Date
July 2009

Phase I Study of the combination of Vandetanib and Dasatinib administered during and after radiation therapy in the children with newly diagnosed DIPG.

Cincinnati Children's Hospital - $50,000

Amount
$50,000.00
Date
September 2008

Study of Radiotherapy and concurrent Bevacizumab +/- Temozolamide followed by Bevacizumab, Irinotecan +/- Temozolamide in patients with newly diagnosed high grade gliomas and DIPG.

St. Jude's Children's Research Hospital - $25,000

Amount
$25,000.00
Date
September 2008

Molecular Analysis of Diffuse Intrinsic Pontine Gliomas.